Community Pharmacists as Immunization Advocates
Cost-Effectiveness of a Cue to Influenza Vaccination
Bibliographic Data
| ID | 9102583 |
|---|---|
| Authors | John D Grabenstein (0000-0003-0404-2198, Walter Reed Army Institute of Research, corresponding author), Abraham G Hartzema (0000-0002-3158-3400, University of North Carolina at Chapel Hill), Harry A Guess (University of North Carolina at Chapel Hill), William P Johnston (University of North Carolina at Chapel Hill), Brian E Rittenhouse, B Rittenhouse (0000-0002-9928-2583, University of North Carolina at Chapel Hill) |
| Year | 1992 |
| Volume | 30 |
| Issue | 6 |
| Pages | 503-513 |
| Publication date | 1992-06-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/00005650-199206000-00004 |
| PMID | 1593916 |
| OpenAlex | W2047128739 |
| Language | EN |
To assess the cost-effectiveness of a cue to influenza vaccination provided by community pharmacists, a decision tree was constructed of the consequences of implementing a pharmacy-based vaccine-advocacy program, based on experience gained in an experiment involving three community pharmacies in Durham County, North Carolina. The model used morbidity and mortality assumptions derived from the infectious-disease literature and cost assumptions based on 1990-91 Medicare Part A and Part B reimbursement costs. This analysis suggests that if Medicare reimbursed pharmacists for advising 100,000 patients at risk to accept influenza vaccine through vaccine-advocacy messages, for an apparent expenditure of $110,000, the increased rate of influenza vaccinations would avert 139 hospitalizations and 63 deaths, and actually yield Medicare a net savings of $280,588. These calculations probably underestimate the benefit to society of a pharmacy-based vaccine-advocacy program, because only direct costs to the single government agency were computed and no cost was attributed to death or lost earnings
Agency (philosophy) · Business · Earnings · Economic growth · Economics · Family medicine · Government (linguistics) · Health care · Immunization · Influenza vaccine · Reimbursement · Vaccination · COVID-19 epidemiological studies · Finance · Immunology · Influenza Virus Research Studies · Medicine · Pharmacy · Vaccine Coverage and Hesitancy
| Highly cited | No |
|---|